Utama › Kanser Paru-paru › Nebraska
Kajian klinikal Kanser Paru-paru di Nebraska
19 kajian untuk Kanser Paru-paru sedang mencari peserta di lokasi di Nebraska.
Bandar di Nebraska
Teks kajian rasmi (Bahasa Inggeris)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Nebraska Medicine-Bellevue, Bellevue
- Fred and Pamela Buffett Cancer Center - Kearney, Kearney
- CHI Health Good Samaritan, Kearney
- dan 5 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04267848Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- CHI Health Saint Francis, Grand Island
- CHI Health Good Samaritan, Kearney
- Alegent Health Immanuel Medical Center, Omaha
- dan 2 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Cancer Partners of Nebraska, Lincoln
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT04181060Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NHO Revive Research Institute, LLC, Lincoln
- NHO Support Center, Lincoln
- Cancer Partners of Nebraska, Lincoln
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07222566Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- Cancer Partners of Nebraska, Lincoln
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07489066This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Fremont, Fremont
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island, Grand Island
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Regional, Grand Island
- dan 5 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06758401A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07063745Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Omaha
Mengambil pesertaFasa 2
Umur 18 hingga 95 · Semua jantina · Dikemas kini 23 Sep 2026 · NCT05061550Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Mary Lanning Healthcare (MLH) - Morrison Cancer Center (MCC), Hastings
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06712316A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- NHO Revive Research Institute, Lincoln
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06793215Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Nebraska Hematology-Oncology (NHO), Lincoln
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Sep 2026 · NCT06712355Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
- Nebraska Methodist Hospital, Omaha
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT05624996Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Nebraska Cancer Specialists, Omaha
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jul 2026 · NCT04198766A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
- University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Jul 2026 · NCT05242965Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Nebraska Cancer Specialist, Grand Island
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Jun 2026 · NCT06162221Integrated Cancer Repository for Cancer Research
- Mary Lanning Healthcare, Morrison Cancer Center, Hastings
- Faith Regional Health Services, Carson Cancer Center, Norfolk
- Great Plains Regional Medical Center, North Platte
- dan 3 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 2
Umur 18 hingga 70 · Semua jantina · Dikemas kini 26 Jun 2026 · NCT04614103Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- Nebraska Cancer Specialists, Omaha
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Mei 2026 · NCT06922591SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Omaha
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.